- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.02. | VITRAFY LIFE SCIENCES LIMITED: Change of Director's Interest Notice | 2 | ASX | ||
| 03.02. | VITRAFY LIFE SCIENCES LIMITED: FY26 Half Year Results Presentation | - | ASX | ||
| 03.02. | VITRAFY LIFE SCIENCES LIMITED: FY26 Appendix 4D and Half Year Report | - | ASX | ||
| 02.02. | VITRAFY LIFE SCIENCES LIMITED: Vitrafy FY26 Half Year Investor Briefing | - | ASX | ||
| 29.01. | Vitrafy Life Sciences Q2 FY26 slides highlight animal health deal and U.S. expansion | 2 | Investing.com | ||
| 28.01. | VITRAFY LIFE SCIENCES LIMITED: Vitrafy Q2 FY26 Investor Briefing | 2 | ASX | ||
| VITRAFY LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 19.01. | VITRAFY LIFE SCIENCES LIMITED: Initial Director's Interest Notice | - | ASX | ||
| 19.01. | VITRAFY LIFE SCIENCES LIMITED: Appointment of Independent Non-Executive Director | - | ASX | ||
| 19.01. | VITRAFY LIFE SCIENCES LIMITED: Change in substantial holding from RYD | - | ASX | ||
| 14.01. | VITRAFY LIFE SCIENCES LIMITED: IMV Strategic Commercial Agreement Investor Briefing | - | ASX | ||
| 14.01. | VITRAFY LIFE SCIENCES LIMITED: IMV Strategic Partnership Investor Presentation | - | ASX | ||
| 14.01. | VITRAFY LIFE SCIENCES LIMITED: Vitrafy Enters Strategic Commercial Agreement with IMV | - | ASX | ||
| 14.12.25 | VITRAFY LIFE SCIENCES LIMITED: Change of Director's Interest Notice | - | ASX | ||
| 14.12.25 | VITRAFY LIFE SCIENCES LIMITED: Notification regarding unquoted securities - VFY | - | ASX | ||
| 21.11.25 | VITRAFY LIFE SCIENCES LIMITED: Change of Director's Interest Notice | - | ASX | ||
| 21.11.25 | VITRAFY LIFE SCIENCES LIMITED: Notification of cessation of securities - VFY | 2 | ASX | ||
| 20.11.25 | VITRAFY LIFE SCIENCES LIMITED: Final Director's Interest Notices | - | ASX | ||
| 20.11.25 | VITRAFY LIFE SCIENCES LIMITED: Application for quotation of securities - VFY | - | ASX | ||
| 20.11.25 | VITRAFY LIFE SCIENCES LIMITED: Results of 2025 Annual General Meeting | - | ASX | ||
| 20.11.25 | VITRAFY LIFE SCIENCES LIMITED: 2025 Annual General Meeting Chair Address & Presentation | 1 | ASX |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BEAM THERAPEUTICS | 25,170 | 0,00 % | Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street | $100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 30,050 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| MAZE THERAPEUTICS | 49,430 | 0,00 % | Truist initiates Maze Therapeutics stock coverage with buy rating | ||
| TAYSHA GENE THERAPIES | 4,560 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update | Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate... ► Artikel lesen | |
| ARCELLX | 114,34 | -0,16 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| QIAGEN | 34,765 | -1,39 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen bei unverändertem Kursziel von 54 US-Dollar von "Hold" auf "Buy" hochgestuft. Analyst Jan Koch kehrt nach seiner Abstufung im Januar... ► Artikel lesen | |
| ALX ONCOLOGY | 2,190 | 0,00 % | Wells Fargo initiates ALX Oncology stock with overweight rating | ||
| FULCRUM THERAPEUTICS | 7,040 | 0,00 % | Fulcrum Therapeutics, Inc.: MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle ... | ||
| ERASCA | 15,260 | 0,00 % | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results | Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics... ► Artikel lesen | |
| LENZ THERAPEUTICS | 11,490 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign | Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours The "Make it VIZZable" campaign features SJP enjoying... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 21,395 | +0,40 % | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,600 | 0,00 % | Cogent Biosciences Stock Climbs After FDA Accepts Key Drug Application | ||
| BIONTECH | 76,70 | -0,78 % | BioNTech-Aktie: Vielen Dank, und tschüss! | Die Nachricht über den Gründer-Rückzug bei BioNTech löste zunächst einen regelrechten Ausverkauf aus. Die Aktie des deutschen mRNA-Spezialisten brach im Tief um rund 25% ein. Die folgende kurzfristige... ► Artikel lesen | |
| ADMA BIOLOGICS | 15,030 | 0,00 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| CG ONCOLOGY | 65,89 | 0,00 % | CG Oncology stock rating reiterated at Buy by Truist Securities |
VITRAFY LIFE SCIENCES LIMITED gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VITRAFY LIFE SCIENCES LIMITED finden Sie auf Wallstreet Online.